Source link : https://www.newshealth.biz/health-news/rnai-win-in-attr-cm-hf-congestion-monitor-approved-lpa-in-stent-restenosis/
Vutrisiran (Amvuttra), an RNA-interfering (RNAi) therapy, reduced hard events and disease progression in transthyretin amyloidosis cardiomyopathy (ATTR-CM) regardless of background tafamidis (Vyndamax, Vyndaqel) therapy, according to HELIOS-B phase III study results announced by Alnylam Pharmaceuticals. Aspirin remains widely used in the U.S. for primary and secondary prevention despite its prevalence drifting downward from 2012 to […]
Author : News Health
Publish date : 2024-06-25 18:35:06
Copyright for syndicated content belongs to the linked Source.
Categories